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SELECTION OF THE MONTH 
Title of the Month: Ageing increases risk of alcohol related liver fibrosis 
 
Cirrhosis (small title): 50% children with chronic liver disease have hepatic 
encephalopathy 
Treating the extreme - When is old too old for HCV treatment? 
 
LIVER REGENERATION 
Indian hedgehog protein accelerates liver regeneration 
Portal vein ligation (PVL)-induced liver growth is being exploited for the surgical 
removal of certain liver tumors. A novel approach called associating liver partition and 
portal vein ligation for staged hepatectomy (ALPPS) combines PVL with parenchymal 
transection. This accelerates compensatory growth, enabling much faster and more 
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extensive tumor removal. Langiewicz et al. addressed the role of secreted factors in 
the acceleration of the regenerative process following ALPPS. They found that Indian 
hedgehog protein (short name: IHH) and subsequent and hedgehog pathway 
activation is the first signal for the acceleration of liver regeneration following 
ALPPS surgery in mice. Moreover, they showed elevated plasma IHH early after 
ALPPS surgery in humans. Using recombinant IHH may have a potential interest in 
stimulating liver regeneration. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Regional inequities in HCC management in France, AFP model for predicting 
HCC recurrence, toward immunotherapy for HCC? 
Little is known on the incidence, management, and prognosis of HCC at the national 
level. Here, Goutte et al. investigated data from French administrative databases for 
more than 30,000 patients with HCC diagnosed between 2009 and 2012, followed up 
to 2013. They reveal that despite full insurance coverage for all citizens, national 
measures to reduce inequities in the management of cancer patients, 
standardized recommendations for HCC surveillance and management, the 
percentage of patients undergoing curative treatment and their survival may 
vary fourfold depending on their postcode. The hospital in which patients are first 
managed influences both accessibility to good care and survival. 
The French study group for Liver Transplantation developed a new predictive model 
for HCC recurrence. This model, called AFP model, was based on tumor staging and 
AFP values at listing and follow-up time points. Notarpaolo et al. aimed to evaluate the 
AFP model in a non-French and for this investigated 574 patients transplanted for HCC 
in 4 Italian centers. Of note all patients had chronic viral hepatitis-related cirrhosis. 
They show that the AFP model identifies HCC candidates at low risk of 
recurrence otherwise excluded by Milan criteria. They also suggest that the AFP 
score could be proposed for selection of HCC candidates in programs with a high 
proportion of patients with chronic viral hepatitis-related cirrhosis. 
In the context of cancer, inhibition of T cell cytotoxicity may favor tumor survival. 
Interestingly, two therapeutic approaches used for HCC, transcatheter arterial 
chemoembolization (TACE) and ablation by themselves have been shown to induce a 
peripheral immune response which might have anti-tumor effects. Of note, T cells 
require two signals for optimal activation. The first signal is delivered to the T cell 
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receptor (TCR) by processed antigen displayed by major histocompatibility complex 
(MHC) molecules. The second signal, known as the costimulatory signal, is delivered 
to receptors on T cells by costimulatory molecules. Costimulatory signals can have 
either stimulatory or inhibitory effects on T cells. The best described costimulatory 
interactions are those in the B7/CD28 family. B7 family members typically act as 
ligands for CD28 receptor family members. For example, B7-1 or B7-2 expressed at 
the surface of antigen-presenting cells engage cytotoxic T lymphocyte-associated 
protein-4 (CTLA-4, also known as CD152) to inhibit TCR-mediated activation. 
Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 and results 
in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation. Duffy et al. 
addressed the hypothesis that, in HCC, peripheral immune stimulation induced by the 
ablative procedure could be amplified by blockade of the B7-CTLA-4-mediated T-cell 
inhibition. For this, they conducted a pilot study in 32 patients with HCC. They show 
that tremelimumab in combination with tumor ablation in patients with advanced 
HCC is safe and that an increase in intra-tumoral CD8+ T cells occurs among 
patients who benefit the combination therapy. 
 
ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASE (ALD AND NAFLD). 
Determinants of prognosis in ALD and role of sirtuin 1 on the effect of age and 
PARP 
Compared to NAFLD, few studies have investigated the determinants of disease 
progression in patients with ALD. Lackner et al. assessed the prognostic impact of 
clinical, biochemical and histological parameters on long-term prognosis in patients 
with early/compensated and decompensated ALD. In early/compensated ALD 
patients, long-term prognosis was determined by fibrosis stage, but not by clinical 
or biochemical variables. Importantly, severe fibrosis was present in have of the 
patients with compensated disease. In decompensated patients, markers of liver 
failure (bilirubin, INR), and pericellular fibrosis predicted long-term survival. 
Remarkably, abstinence was an important predictor of survival in both 
early/compensated and decompensated ALD. Besides this clinical study, an intriguing 
paper in this issue investigates the mechanisms by which aging exacerbates the 
progression of ALD. Ramirez el al. demonstrate that, compared to young mice, middle-
aged and old mice are more susceptible to alcohol-induced liver injury. 
Importantly, restoring hepatic expression of sirtuin 1 (Gene Symbol: Sirt1), which 
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is markedly lower in older mice, ameliorates subacute liver injury induced by alcohol 
and also the fibrogenic response to chronic liver injury. A role for Sirt1 in mediating 
the effects of aging in experimental ALD was confirmed in Sirt1-deficient mice. These 
intriguing results were confirmed at the cellular level, since hepatic stellate cells from 
older mice express lower levels of the Sirt1 gene product, which regulates their 
profibrogenic actions. This important study shows that aging exacerbates ALD in mice 
through the downregulation of Sirt1 in the liver. Finally, a third study by Mukhopadhyay 
et al. investigates the role of Poly(ADPribose) polymerases (PARPs), key regulators of 
intermediary metabolism through SIRT1, on alcoholic and nonalcoholic steatohepatitis 
(ASH/NASH). The authors found PARP activity increased in ASH livers together with 
decreased NAD+ content and SIRT1 activity. Pharmacological and/or genetic 
ablation of PARP attenuated the decrease in SIRT1 activation and reduced 
hepatic triglyceride accumulation, metabolic dysregulation, or inflammation 
and/or fibrosis in models of Ash and NASH. These results suggest that PARP 
inhibition is a promising therapeutic strategy in steatohepatitis. 
 
HEPATITIS B VIRUS (HBV) INFECTION  
Liver disease progression in HBV infection, stem cell-derived hepatocyte-like 
cells to study the biology of HBV infection  
Liver and non-liver related risk factors may contribute to the prognosis of patients 
chronically infected with HBV. However, neither these factors per se nor their relative 
contribution to the population-based risk of HBV disease progression have been well 
defined in the Western world. In the largest Western cohort studied so far including 
48,189 HBV-infected patients, Mallet et al. showed that about three-quarters of 
patients with chronic hepatitis B who progressed to a liver-related complication, 
including liver transplantation and liver-related death, had an additional liver-
related risk factor. For hepatitis D virus co-infection, hepatitis C virus co-infection, 
alcohol use disorders, diabetes mellitus, and other rare causes of chronic liver the 
adjusted hazard ratios for liver disease progression of disease were 1.44, 1.77, 3.37, 
1.40, and 2.19, respectively. The fact that HBV HIV co-infected patients without AIDS 
had better outcomes, despite a higher prevalence of liver-related risk factors, may be 
taken as a hint how improved linkage to care provided to this special patient population 
can be also a concept to improve long-term prognosis also in HBV mono-infected 
patients. 
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Although HBV was identified more than 50 years ago many fundamental aspects of 
the virus’ biology remain poorly understood mainly due to the lack of physiological cell 
culture systems permitting efficient HBV infection, replication and dissemination. Xia 
et al. described a novel in vitro HBV infection model, based on stem cell-derived 
hepatocyte-like cells (HLCs), that fully supports HBV infection for at least one 
month. HLCs closely resemble primary human hepatocytes, which makes them 
suitable for many applications including virus-host interaction studies and drug 
development in genetically defined hepatocytes but also HBV spreading. By using this 
model, authors also identified two host-targeting agents, Genistin and PA452, as novel 
antivirals against HBV infection. This robust model offers a unique opportunity to 
advance our understanding of the molecular mechanisms of HBV life cycle, to further 
characterize virus-host interactions, and to define new targets for HBV curative 
treatment. 
 
HEPATITIS C VIRUS (HCV) INFECTION  
What happens after HCV eradication? Treating the extreme - When is old too old 
for HCV treatment? 
With the increasing number of patients achieving direct antiviral agents (DAA)-induced 
sustained viral eradication (SVR) there is increasing interest in studying the SVR-
associated long-term consequences, and to figure out to what extent viral eradication 
also translates into a reduction of liver disease-associated complications – mainly HCC 
development. Van der Meer et al. followed 1000 patients from previously reported 
Western cohort studies with chronic HCV infection and bridging fibrosis or cirrhosis 
who attained SVR. The study confirmed an annual HCC risk after SVR of 
approximately 1% in HCV-induced cirrhosis but also showed for the first time a 
significant risk of clinical disease progression. After 8 years 4.2% of patients with 
bridging fibrosis and 15.8% of patients with cirrhosis experienced clinical disease 
progression. In a second study in this issue the effect of SVR on the estimated HCC 
incidence post SVR was evaluated by Janjuain et al. in a large population-based 
Canadian cohort (N=8,147). SVR after interferon-based treatment substantially 
reduced HCC risk with an incidence rate of 1.1/1000 person-years (PY) as 
compared to 7.2/1000 PY among the non-SVR group. Factors associated with HCC 
development post-SVR were cirrhosis, age ≥ 50 years and being male. These studies 
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highlight the need of early HCV diagnosis and to start HCV eradication before 
advanced fibrosis is established.  
Extremely aged patients, i.e., those aged 80 years or older, have been rarely 
considered eligible for antiviral treatment in the interferon era, and it remains to be 
seen whether this population derives similar clinical benefits from DAA-induced HCV 
eradication as younger patients. In the present study, Toyoda et al. analysed the 
efficacy and tolerability of an interferon-free daclatasvir plus asunaprevir regimen in 
patients ≥ 80 years, and compared the results with those of patients aged ≥ 70 and < 
80 years and those aged <70 years. They found a similar tolerability and efficacy of 
the DAA regimen irrespective of patients’ age but more importantly, the HCV 
eradication resulted in a significant survival benefit even in patients aged ≥ 80 
years. In ≥ 80 years-old patients with persistent HCV infection, the 1-year mortality 
due to liver-related diseases was 8.1%, but none of the patients with SVR died from 
liver disease. According to the results of this important study there seems to be no age 
limit at which one should withheld DAA treatment in the increasingly ageing HCV 
infected population.   
 
CIRRHOSIS 
50% children with chronic liver disease have minimal hepatic encephalopathy 
Minimal hepatic encephalopathy (MHE) is a common feature of cirrhosis in adults but 
its presence, frequency and pathophysiology is not clear in children with chronic liver 
disease. The paper by Srivastava et al. provides the first comprehensive insight 
into the problem suggesting that about 50% of children with chronic liver 
disease have features of MHE, that may result in poor quality of life, risk of overt 
HE and mortality. Parameters identified on MRI scanning had a high sensitivity and 
specificity for identification of those with MHE. The paper also describes that the 
pathophysiological mechanisms underlying this syndrome is similar to that in adults, 
suggesting that clinical trials of available agents to treat MHE may be justifiable in 
children as well. Although further validation of these data is needed, this seminal 
observation will allow further studies. 
 
CHOLESTASIS 
ACOX2 deficiency as a novel cause of abnormal liver function of unknown cause 
ACOX2 (official full name: acyl-coenzyme A oxidase 2) encodes a peroxisomal 
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enzyme involved in shortening of C27 cholesterol derivatives to C24 bile acids. 
Deficiencies in the metabolic pathways of cholesterol-bile acid metabolism have been 
shown to be associated with hepatic and neurologic dysfunction. In looking for 
possible mechanisms underlying abnormal liver function tests in an adolescent 
patient, Marin et al. discovered for the first time evidence of ACOX2 deficiency 
as the underlying cause. They showed that this patient had evidence of elevated C27 
intermediates but almost completely absent C24 metabolites. Exons 
amplification/sequencing of enzymes potentially involved revealed a homozygous 
missense mutation (c.673C>T; R225W) in ACOX2. Other data generated by the group 
provide and insight into the operative mechanisms. This case study may have 
relevance to investigating patients with abnormal function tests of unknown cause.  
 
